Mytos

Every year, millions of patients miss out on life-changing cell therapies because the manufacturing process remains prohibitively expensive and difficult to scale. Mytos exists to change that by automating the complex and time-consuming process of growing human cells for regenerative medicine.

The company has developed the iDEM™ automation technology platform, which fully automates critical unit operations in cell culture including coating, seeding, feeding, cell imaging, passaging, and harvesting. Unlike traditional manual cell manufacturing that requires scientists to spend hours daily tending to cells, Mytos's robotic systems enable scalable, consistent production at dramatically reduced costs. Their platform operates within a closed system using standard 2D T flask formats, allowing manual protocols to be rapidly ported to automated workflows without compromising the biology. The company functions as an automated Contract Development and Manufacturing Organization (CDMO), with their first manufacturing site housed within the Cell and Gene Therapy Catapult's 80,000 square foot facility. Mytos has established strategic partnerships with biotech companies working on treatments for Parkinson's disease, hearing loss, corneal blindness, and bone repair, bringing transformative cell therapies to patients worldwide.